BioCardia, Inc. (BCDA)

NASDAQ: BCDA · Real-Time Price · USD
1.970
+0.155 (8.54%)
Apr 25, 2025, 4:00 PM EDT - Market closed
8.54%
Market Cap 9.22M
Revenue (ttm) 58,000
Net Income (ttm) -7.95M
Shares Out 4.68M
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,539
Open 1.780
Previous Close 1.815
Day's Range 1.780 - 1.970
52-Week Range 1.630 - 6.150
Beta 1.21
Analysts Strong Buy
Price Target 25.00 (+1,169.04%)
Earnings Date May 13, 2025

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bon... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Peter Altman
Employees 20
Stock Exchange NASDAQ
Ticker Symbol BCDA
Full Company Profile

Financial Performance

In 2024, BioCardia's revenue was $58,000, a decrease of -87.84% compared to the previous year's $477,000. Losses were -$7.95 million, -31.33% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $25.0.

Price Target
$25.0
(1,169.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress

14 days ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief ...

25 days ago - Seeking Alpha

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...

25 days ago - GlobeNewsWire

BioCardia Reports 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

4 weeks ago - GlobeNewsWire

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...

5 weeks ago - GlobeNewsWire

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea...

6 weeks ago - GlobeNewsWire

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...

2 months ago - GlobeNewsWire

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (...

2 months ago - GlobeNewsWire

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have be...

3 months ago - GlobeNewsWire

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...

5 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chi...

5 months ago - Seeking Alpha

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...

7 months ago - GlobeNewsWire

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...

8 months ago - GlobeNewsWire

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...

8 months ago - GlobeNewsWire

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial

8 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief...

9 months ago - Seeking Alpha

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...

9 months ago - GlobeNewsWire

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disea...

10 months ago - GlobeNewsWire

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.

11 months ago - GlobeNewsWire

BioCardia Announces Reverse Stock Split

SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

1 year ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Miranda Peto - IR Peter Altman - President and CEO David McClung - CFO Conference Call Part...

1 year ago - Seeking Alpha

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

1 year ago - GlobeNewsWire

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

1 year ago - GlobeNewsWire

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

1 year ago - GlobeNewsWire

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomize...

1 year ago - GlobeNewsWire